UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026
Commission File Number: 001-42450
Zhengye Biotechnology Holding Limited
No. 1 Lianmeng Road, Jilin Economic & Technical Development Zone
Jilin City, Jilin Province, China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Explanatory Note
Zhengye Biotechnology Holding Limited (the “Company”) issued a press release on July 21, 2026, announcing the Company’s comments in response to recent unusual trading activity in the price and trading volume of its Class A ordinary shares. A copy of this press release is attached hereto as Exhibit 99.1, and is incorporated by reference herein.
1
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press release — Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: July 21, 2026
| Zhengye Biotechnology Holding Limited | ||
| By: | /s/ Songlin Song | |
| Name: | Songlin Song | |
| Title: | Chief Executive Officer | |
3